

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF CALIFORNIA

JUDITH JANNEY, et al.,  
Plaintiffs,  
v.  
GENERAL MILLS,  
Defendant.

Case No. [12-cv-03919-WHO](#)

**ORDER DENYING MOTION TO STAY**  
Re: Dkt. No. 66

**INTRODUCTION**

Plaintiffs Judith Janney and Amy McKendrick bring this putative class action against defendant General Mills, Inc., asserting that the use of the term “Natural” on General Mills’s “Nature Valley” products (the “products”) is deceptive and misleading because of the presence of high fructose corn syrup (“HFCS”), high maltose corn syrup (“HMCS”), and maltodextrin. General Mills moves to stay the proceedings based on the argument that the United States Food and Drug Administration (“FDA”) has primary jurisdiction over the term “natural” and two judges, including one in this district, have stayed their cases pending a response to a referral to the FDA the question of whether products with bioengineered ingredients may be labeled “natural.” General Mills also argues that the Court should exercise its inherent authority to stay this case. After considering the parties’ briefs and argument, and for the reasons below, General Mills’s Motion to Stay is DENIED.

**BACKGROUND**

The Complaint alleges the following:

Plaintiff Judith Janney “purchased Nature Valley Chewy Trail Mix Dark Chocolate & Nut Granola Bars and Nature Valley Peanut Butter Granola Thins” repeatedly for two years or more,

1 with her last purchase occurring in March 2012. Second Amended Compl. (“SAC”) (Dkt. No. 59)  
2 ¶¶ 16, 44 & 45. Plaintiff Amy McKendrick “purchased Nature Valley Chewy Trail Mix Fruit &  
3 Nut Granola Bars, Nature Valley Sweet & Salty Nut Cashew Granola Bars, and Nature Valley  
4 Dark Chocolate and Peanut Butter Granola Thins,” with her last purchase occurring in February or  
5 March 2012. *Id.* ¶¶ 17 & 50. They relied “on the claims that they are ‘Natural.’” *Id.* ¶ 42. The  
6 plaintiffs “would not have bought the [products] if they had known that they were not in fact  
7 natural products.” *Id.* ¶ 23.

8 The products “contain the highly processed sugar substitute HFCS, HMCS, and the  
9 texturizer Maltodextrin.” *Id.* ¶ 24. “HFCS and HMCS are sweeteners created from cornstarch, as  
10 opposed to sugar (sucrose), which is produced from sugar cane or beets,” and “[m]altodextrin is a  
11 texturizer used in processed foods and is created from starch as well.” *Id.* ¶¶ 26 & 27. Because  
12 producing these ingredients “requires multiple processing steps in an industrial environment,  
13 which transform starches into substances that are not found in nature, they cannot be described as  
14 ‘Natural.’” *Id.* ¶ 27.

15 The “Natural” claim appears in varying forms on the fronts and backs of the products’  
16 boxes, as well as on the granola bars’ individual packaging. *Id.* ¶¶ 35-41. Despite a letter from  
17 the plaintiffs to General Mills detailing their concerns, General Mills “has failed to change its  
18 practice of including HMCS and Maltodextrin in products with ‘Natural’ claims.”<sup>1</sup> *Id.* ¶ 58.

19 “Plaintiffs were attracted to the [products] because they prefer to consume all-natural  
20 foods for reasons of health, safety, and environmental preservation.” *Id.* ¶ 42. Additionally,  
21 because of her diabetic daughter, Janney “seeks out healthier food and food that is all natural,” and  
22 McKendrick purchases all natural products for her daughter because she finds that “an all-natural  
23 diet seems to help alleviate her daughter’s behavioral issues,” such as attention deficit  
24 hyperactivity disorder. *Id.* ¶¶ 43 & 47. Because the plaintiffs “believe that all-natural foods  
25 contain only ingredients that occur in nature or are minimally processed,” these products, “with  
26 their deceptive ‘Natural’ claims, have no value to the Plaintiffs.” *Id.* ¶ 42.

27 \_\_\_\_\_  
28 <sup>1</sup> In 2010, General Mills claimed that it would phase out its use of HFCS in its products within a  
year. The plaintiffs do not indicate if General Mills has, in fact, done this. SAC ¶ 56.

1 **PROCEDURAL HISTORY**

2 The plaintiffs bring this putative class action on behalf of “all persons in California who  
3 bought the [products] that contained HFCS, HMCS, and Maltodextrin and were labeled ‘Natural’  
4 during the period beginning four years prior to the date the original complaint was filed until the  
5 date of class certification.” *Id.* ¶ 59. They bring the following causes of action: (1) violation of  
6 the California Consumers Legal Remedies Act, CAL. CIV. CODE §§ 1750 *et seq.*; (2) violation of  
7 the California Unfair Competition Law, CAL. BUS. & PROF. CODE §§ 17200 *et seq.*; (3) violation  
8 of the California False Advertising Law, CAL. BUS. & PROF. CODE §§ 17500 *et seq.*; and (4) unjust  
9 enrichment.

10 On May 10, 2013, the Honorable Phyllis Hamilton granted in part and denied in part  
11 General Mills’s Motion to Dismiss the plaintiffs’ First Amended Complaint. Dkt. No. 56. In  
12 considering the motion, Judge Hamilton refused to invoke the primary jurisdiction doctrine and  
13 cited the FDA’s longstanding refusal to promulgate regulations governing the use of the term  
14 “natural” and its “relative lack of interest in devoting its limited resources to what it evidently  
15 considers a minor issue” in concluding that any referral to the FDA “would likely prove futile.”

16 On July 29, 2013, the Court related this case with two others in this district: *Bohac v.*  
17 *General Mills, Inc.*, No. 12-cv-5280, and *Rojas v. General Mills, Inc.*, No. 12-cv-5099.

18 General Mills again asks the Court to stay the case based on the primary jurisdiction  
19 doctrine and the court’s inherent case-management authority. General Mills contends that a stay is  
20 especially appropriate in light of the recent referral by a judge in this district to the FDA the issue  
21 of whether products with bioengineered ingredients may be labeled “natural.” *See Cox v. Gruma*  
22 *Corp.*, No. 12-cv-6502, 2013 WL 3828800, at \*2 (N.D. Cal. July 11, 2013). General Mills also  
23 notes that a judge in the District of Colorado stayed a similar case pending a response from the  
24 FDA to the *Cox* referral. *See Van Atta v. Gen. Mills, Inc.*, No. 12-cv-2815-MSK-MJW (D. Colo.  
25 July 18, 2013).

1 **DISCUSSION<sup>2</sup>**

2 **I. THE PRIMARY JURISDICTION DOCTRINE DOES NOT APPLY.**

3 Judges in this district have repeatedly declined invoking the primary jurisdiction doctrine  
4 in cases asking whether the term “natural” as used on food labels is false or misleading, as the  
5 judge previously assigned to this case did here. *See Janney v. General Mills*, No. 12-cv-3919-  
6 PJH, 2013 WL 1962360, at \*7 (N.D. Cal. May 10, 2013) (Hamilton, J.); *see also Kosta v. Del*  
7 *Monte Corp.*, No. 12-cv-1722-YGR, 2013 WL 2147413, (N.D. Cal. May 15, 2013); *Brazil v. Dole*  
8 *Food Co.*, No. 12-cv-1831-LHK, 2013 WL 1209955, at \*10 (N.D. Cal. March 25, 2013); *Ivie v.*  
9 *Kraft Foods Global, Inc.*, No. 12-cv-2554-RMW, 2013 WL 685372, at \*7 (N.D. Cal. Feb. 25,  
10 2013); *Jones v. ConAgra Foods, Inc.*, 912 F. Supp. 2d 889, 898-99 (N.D. Cal. 2012) (Breyer, J.).  
11 The Court finds no reason to depart from their considered judgment.

12 “The [primary jurisdiction] doctrine is applicable whenever the enforcement of a claim  
13 subject to a specific regulatory scheme requires resolution of issues that are within the special  
14 competence of an administrative body.” *Farley Transp. Co. v. Santa Fe Trail Transp. Co.*, 778  
15 F.2d 1365, 1370 (9th Cir. 1985) (quotation marks omitted). “The doctrine does not, however,  
16 require that all claims within an agency’s purview be decided by the agency.” *Davel Commc’ns,*  
17 *Inc. v. Qwest Corp.*, 460 F.3d 1075, 1086 (9th Cir. 2006) (citation and quotation marks omitted).  
18 The Ninth Circuit has applied four non-exclusive factors identified in *United States v. General*  
19 *Dynamics Corp.*, 828 F.2d 1356 (9th Cir. 1987), to determine whether the doctrine applies.  
20 “Under this test, the doctrine applies where there is ‘(1) the need to resolve an issue that (2) has  
21 been placed by Congress within the jurisdiction of an administrative body having regulatory  
22 authority (3) pursuant to a statute that subjects an industry or activity to a comprehensive  
23 regulatory scheme that (4) requires expertise or uniformity in administration.’” *Davel Commc’ns,*  
24 460 F.3d at 1086 (quoting *Gen. Dynamics Corp.*, 828 F.2d at 1362).

25 Invocation of the doctrine is appropriate where a case “requires resolution of an issue of  
26 first impression” or when the issue is not “within the conventional experience of judges.” *Brown*

27 \_\_\_\_\_  
28 <sup>2</sup> This section is substantially similar to the Discussion in the Court’s Order Denying Motion to  
Stay in *Bohac v. General Mills, Inc.*, No. 12-cv-5280.

1 *v. MCI WorldCom Network Servs., Inc.*, 277 F.3d 1166, 1172 (9th Cir. 2002) (citing *Nat'l*  
 2 *Commc'ns Ass'n. v. AT&T Corp.*, 46 F.3d 220, 222 (2d Cir. 1995)); *see also Clark v. Time Warner*  
 3 *Cable*, 523 F.3d 1110, 1114 (9th Cir. 2008) (“the doctrine is a ‘prudential’ one, under which a  
 4 court determines that an otherwise cognizable claim implicates technical and policy questions that  
 5 should be addressed *in the first instance* by the agency with regulatory authority over the relevant  
 6 industry rather than by the judicial branch”) (emphasis added). A court may decline to hear a case  
 7 if it determines that the doctrine applies. *Id.* at 1088.

8 While issues related to food labeling are undoubtedly within the expertise of the FDA, this  
 9 case does not involve a situation in which the Court should abstain from deciding the questions  
 10 before it. Deciding what “natural” means is not “an issue of first impression” or one that has not  
 11 been addressed “in the first instance” by the FDA. *Brown*, 277 F.3d at 1172; *Clark*, 523 F.3d at  
 12 1114. As General Mills itself concedes, “the FDA has adopted a policy for use [of] the word  
 13 ‘natural’ on food labels, one that it enforces through administrative action.” Br. (Dkt. No. 66) at  
 14 12. It quotes the FDA as stating that “natural” means “that nothing artificial or synthetic . . . has  
 15 been included in, or has been added to, a food that would not normally be expected to be in the  
 16 food.” Br. 9-10 (internal quotation marks omitted). Given the amount of attention that the FDA  
 17 has apparently directed towards the issue before the Court, “there is no such risk of undercutting  
 18 the FDA’s judgment and authority by virtue of making independent determinations on issues upon  
 19 which there are no FDA rules or regulations (or even informal policy statements).” *Brazil*, 2013  
 20 WL 1209955, at \*10 (citation and quotation marks omitted).

21 Determining whether a term is false or misleading is within the province of the courts.  
 22 “[A]llegations of deceptive labeling do not require the expertise of the FDA to be resolved in the  
 23 courts, as every day courts decide whether conduct is misleading.” *Jones*, 912 F. Supp. 2d at 898-  
 24 99 (citations and internal quotation marks omitted). This case primarily requires asking whether a  
 25 “reasonable consumer” would be misled by the challenged statements—what a “reasonable  
 26 consumer” thinks does not involve answering technical questions or scientific expertise. *See*  
 27 *Chacanaca v. Quaker Oats Co.*, 752 F. Supp. 2d 1111, 1124 (N.D. Cal. 2010) (“plaintiffs advance  
 28 a relatively straightforward claim: they assert that defendant has violated FDA regulations and

1 marketed a product that could mislead a reasonable consumer. As courts faced with state-law  
2 challenges in the food labeling arena have reasoned, this is a question courts are well-equipped to  
3 handle.”) (citation and quotation marks omitted). Of course, the FDA’s views are “relevant to the  
4 issue of whether these labels could be deceptive or misleading to a reasonable consumer,” *Ivie*,  
5 2013 WL 685372, at \*12, but they are not the sole or dispositive factor. The questions to be  
6 decided here are squarely within “the conventional experience of judges.” *Brown*, 277 F.3d at  
7 1172.

8           The *General Dynamics* factors do not help General Mills. “Without question, the FDA has  
9 extensively regulated food labeling in the context of a labyrinthine regulatory scheme.”  
10 *Chacanaca*, 752 F. Supp. 2d at 1124. Answering the questions of whether the food labeling in  
11 question is false or misleading, however, does not require the FDA’s expertise and “uniformity in  
12 administration” by the FDA does not weigh in favor of abstaining. *Davel Commc’ns*, 460 F.3d at  
13 1086. As Judge Hamilton’s earlier Order in this case concluded, “the FDA has signaled a relative  
14 lack of interest in devoting its limited resources to what it evidently considers a minor issue, or in  
15 establishing some ‘uniformity in administration’ with regard to the use of ‘natural’ in food  
16 labels.”<sup>3</sup> *Janney*, 2013 WL 1962360, at \*7; *see also Jones*, 912 F. Supp. 2d at 898 (“The FDA’s  
17 inaction with respect to the term ‘natural’ implies that the FDA does not believe that the term  
18 ‘natural’ requires ‘uniformity in administration.’”).

19           The Ninth Circuit has made clear that not “all claims within an agency’s purview [must] be  
20 decided by the agency.” *Davel Commc’ns*, 460 F.3d at 1086. *Janney*’s “claims do not necessarily  
21 implicate primary jurisdiction, and the FDA has shown virtually no interest in regulating” the term  
22 “natural.” *Cf. Chavez v. Nestle USA, Inc.*, 511 Fed. App’x 606, 607 (9th Cir. 2013) (discussing  
23 primary jurisdiction doctrine as applied to DHA). After considering these factors, and because  
24 this case is neither an issue of first impression for the FDA nor a particularly complicated issue

25

---

26 <sup>3</sup> General Mills argues that deferring to the FDA will not be futile this time because two cases  
27 involving the term “natural” have now been stayed on primary jurisdiction grounds. Given the  
28 litany of cases in this area over the years, however, the Court is skeptical that the FDA will  
develop a policy regarding the term “natural” anytime soon, especially since it has considered the  
matter for over two decades but still has not provided further guidance. *See Lockwood v. Conagra  
Foods, Inc.*, 597 F. Supp. 2d 1028, 1033 (N.D. Cal. 2009) (Breyer, J.).

1 inappropriate for a court to address, the Court declines to invoke the primary jurisdiction doctrine  
2 as many other courts addressing the same or similar issues have declined to do.

3 General Mills argues that deciding this issue “without the FDA’s input, would risk  
4 usurping the FDA’s interpretive authority and undermining, through private litigation, the FDA’s  
5 considered judgments.” Br. 5 (quoting *Cox v. Gruma Corp.*, No. 12-cv-6502, 2013 WL 3828800  
6 (N.D. Cal. July 11, 2013) (internal quotation marks and brackets omitted). The Court notes that  
7 the *Cox* referral involves “the question of whether and under what circumstances food products  
8 containing ingredients produced using *bioengineered seed* may or may not be labeled ‘Natural’ or  
9 ‘All Natural’ or ‘100% Natural.’” 2013 WL 3828800, at \*2 (emphasis added). In other words, the  
10 referral is limited to the issue of whether *genetically modified organisms* are natural, which are not  
11 the same ingredients at issue here—the FDA is not being asked to broadly define the term  
12 “natural.” Thus, it is unclear why the Court must await the FDA’s opinion on that question. In  
13 any event, as General Mills itself admits, “the FDA has adopted a policy for use [of] the word  
14 ‘natural’ on food labels, one that it enforces through administrative action.” Br. 12. As discussed  
15 above, the issues presented are not ones of first impression for the FDA—the Court is not wading  
16 into uncharted waters. Deciding this case does not mean that the Court shows no deference to the  
17 agency; on the contrary, the views expressed by the agency thus far, even if informal, would likely  
18 be highly relevant to the Court’s determinations. Thus, the Court would not “risk usurping the  
19 FDA’s interpretive authority and undermining, through private litigation, the FDA’s considered  
20 judgments” by hearing this case.

21 *Astiana v. Hain Celestial Group, Inc.*, 2012 WL 5873585 (N.D. Cal. Nov. 19, 2012)—a  
22 case about the use of the term “natural” in cosmetics—is distinguishable from the facts at hand.  
23 As one judge in this district explained, *Astiana* “is inapposite because, unlike cosmetics, the FDA  
24 has provided informal policy guidance stating the minimum standards for using the term “natural”  
25 with respect to food products . . . .” *Kosta*, 2012 WL 5873585, at \*9. Indeed, in declining to  
26 invoke the primary jurisdiction doctrine in her order in this case, Judge Hamilton—the judge in  
27 *Astiana*—explained that “the issuance of the informal ‘policy’ [concerning the term ‘natural’ with  
28 regard to food], or its citation by the FDA when it chooses to do so, suggests that the FDA does

1 have a position of sorts—unlike the situation in *Astiana*, where the FDA had issued no guidance  
2 whatsoever, even informal policy statements, regarding the use of the term ‘natural’ on cosmetics  
3 packaging.” *Janney*, 2013 WL 1962360, at \*7. Given the FDA’s guidance on food labeling to  
4 date, there is little risk of improperly invading the FDA’s primary jurisdiction by hearing this case.

5 **II. THE COURT DECLINES TO EXERCISE ITS DISCRETION TO STAY.**

6 General Mills argues that the Court should exercise its inherent discretion to stay the case.  
7 A district court has broad discretion to stay proceedings pending before it “to control the  
8 disposition of the causes on its docket with economy of time and effort for itself, for counsel, and  
9 for litigants.” *Landis v. N. Am. Co.*, 299 U.S. 248, 254 (1936). The power to stay “calls for the  
10 exercise of judgment, which must weigh competing interests and maintain an even balance.” *Id.* at  
11 254-55. “Among these competing interests are the possible damage which may result from the  
12 granting of a stay, the hardship or inequity which a party may suffer in being required to go  
13 forward, and the orderly course of justice measured in terms of the simplifying or complicating of  
14 issues, proof, and questions of law which could be expected to result from a stay.” *CMAX, Inc. v.*  
15 *Hall*, 300 F.2d 265, 269 (9th Cir. 1962).

16 These factors do not weigh in favor of a stay. General Mills argues that a three-month stay  
17 is modest and will not harm any party, but for the same reason, any harm from proceeding  
18 (primarily, the cost of beginning discovery) is also relatively modest. Outweighing that is the  
19 likelihood that the FDA will not respond to the referral in *Cox* in a meaningful way, given both the  
20 FDA’s history of how it has addressed this issue and the multiplicity of other issues that command  
21 the FDA’s attention. Accordingly, the orderly course of justice will be harmed by a stay: the  
22 likely outcome is that in three months, either General Mills will return to seek a further stay from  
23 the Court or three months of case development will have been delayed. Federal Rule of Civil  
24 Procedure 1 emphasizes the importance of the “just, speedy, and inexpensive determination of  
25 every action and proceeding,” and a stay in this case is more likely to delay justice, slow the  
26 resolution of the matter, and make this litigation more expensive in the long run than simply  
27 moving forward with it. No one knows how the FDA will respond, if it responds at all, so the  
28 initial discovery sought by the plaintiffs might be relevant regardless. Balancing the potential cost




1 to General Mills of commencing discovery against the delay caused by a stay and the likelihood  
2 that the FDA will not definitively and timely resolve the question presented to it, as Judge  
3 Hamilton thoroughly discussed in her Order, the Court declines to exercise its discretion to stay  
4 this case.

5 **CONCLUSION**

6 For the reasons above, General Mills's Motion to Stay is DENIED.

7 **IT IS SO ORDERED.**

8 Dated: October 10, 2013



---

9  
10 WILLIAM H. ORRICK  
United States District Judge

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28